

INDEX

Note: Page numbers in *italics* indicate figures.
Page numbers followed by a “t” indicate tables.
MOA is the abbreviation for mechanisms of action;
AED is the abbreviation for antiepileptic drug.

- Abnormal neuronal firing, 37-39, *40-41*
- Absence seizures
 - augmentation of tonic inhibition and, 61
 - HCN channels and, *91, 92, 93-94*
 - modulatory pathways involved in, *90-91*
 - prevention of, 94
 - T-type calcium channels and, 85-87, *91, 93-94*
 - treatment of, 87
- Acetylcholine, 113
- Action potential, 22, *32-33, 134*
 - in abnormal neuronal firing, 37-39, 38
 - sodium channel inactivation and, *46-47*
 - sodium influx and, 29, 43, 46
 - threshold for, 29
- Adenylate cyclase activation, 36
- ADHD, potassium channel agonists and, 119, *120-121*
- After-hyperpolarization (AHP), *32-33*
- Alcohol, modulation of GABA_A receptors by, *64*
- $\alpha 2\delta$ protein, 97, 100-103, *102, 126t, 134*
- Ampa receptors, 71, *135*. See also *Glutamate receptors*.
 - AED modulators of, 76t, 77-81, 78-80, 125
 - antagonists of, 71, 76-77
 - EPSPs and, 36, 38, 39
 - ion pore of, 76, 78-80, *135*
 - location and function of, 71, 74, *135*
 - role in excitatory neurotransmission, 71, 77
 - role in normal and epileptic firing, 34t, 36
 - role in seizure genesis and spread, 77
 - subunits of, 76t
- Anesthetics
 - general, modulation of GABA_A receptors by, *64, 65t*
 - local, sodium current block by, *48-49*
- Animal models of epilepsy, 15, 94, 97, 100, *101*
- Antiepileptic drugs (AEDs). See also *specific AEDs*.
 - binding sites, determination of, 23-24
 - broad-spectrum, 43, 124, 132-133
 - chemical structures of, 143-147
 - combinations of, xi-xii
 - concentration-response studies, 18
 - development process for, xiii-xiv
 - example of, 133-142, *138-141*
 - factors determining clinical effects of, xii

- Antiepileptic drugs (AEDs) (*continued*)
mechanisms of action
calcium channels and, 85-87, 100-103
classification of, 132t
established AEDs, 126t
in excitatory transmission, 134-135
GABAergic modulators, 59-69, 65t
glutamate receptor modulators, 76t, 77-81, 78-80, 134-135
in inhibitory transmission, 136-137
methods for defining, 15-24, 16t
modulation of neurotransmission, 131-132, 134-137
multiple or unknown, x-xi, 123-130
potassium channels and, 109-118
presynaptic synaptic vesicle 2A (SV2A) and, 97-100, 98-99, 101
reasons for study of, x-xiv
second-generation AEDs, 126t-127t
sodium channels and, 43, 44-45, 47-51, 48-49, 50t, 56-57, 126t-127t, 132t, 134-135
summary of, 126t-127t, 134-137
synthesis and perspectives on, 131-142, 134-137
technology and, leading to seizure control, 138-141
reduction of excitability by, 56-57
seizure induction or exacerbation by, xii-xiii, 61, 94
use dependence of, 47, 50t, 52-53
- Anxiety, potassium channel agonists and, 119, 120-121
- APV, 75
- Astrocytes, 64, 140
- Audiogenic seizure-susceptible mouse, 100, 101
- Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), 24
- Barbiturates
action mechanism of, 23, 136
chloride conductance enhanced by, 23, 61, 66, 136
modulation of GABA_A receptors by, 61, 64, 65t, 66
- Benign familial neonatal convulsions (BFNC), xiii, 24, 113
- Benzodiazepines
action mechanisms of, 23, 94, 136
chloride conductance enhanced by, 23, 66, 136, 140
example of technology and MOAs, leading to seizure control, 133-142, 138-141
modulation of GABA_A receptors by, 61, 64, 65t, 94, 133
prevention of absence seizures by, 94
zonisamide and, 128
- BFNC. See *Benign familial neonatal convulsions*.
- Binding
of AEDs to sodium channels, 44-45, 47
of neurotransmitters to receptors, 35
- Binding sites, determination of, 23-24
- Binding studies, with radiolabeled receptors, 15-16
- Bipolar disease, potassium channel agonists and, 119, 120-121
- Bivaracetam, 97-100, 98-99, 101
- Bradykinin, 113
- Brain
abnormal neuronal firing in, 40-41
thalamocortical connections in, 25-29, 30-31
- Brain slices, electrophysiology on, 22
- Broad-spectrum AEDs, 43, 124, 132-133
- Bursting. See *Epileptiform bursting*.
- Calcium-activated potassium channels, 34t, 110-111, 112t
- Calcium (Ca²⁺) channels, 85-87, 100-103
gabapentin and pregabalin binding to, 100-103, 102, 134
effect on neurotransmitter release, 103, 104-105
high-voltage activated (HVA), 85, 100-103
structure and subunits of, 85, 86
α₂δ subunits, 97, 100-103, 102, 126t-127t, 134
low-voltage activated (T-type), 85-87
absence seizures and thalamocortical rhythmicity and, 85-87, 90-91, 93-94
functional properties of, 88-89
gating kinetics of, 85, 88-89, 94
inhibition by AEDs, 87, 93, 124, 126t-127t, 134-135
structure and subunits of, 85, 86
modulation mechanism, 132t, 134-135
neurotransmitter release, relationship with, 103, 104-107, 134-135
role in normal and epileptic firing, 29, 34t, 85-86
structure and subunits of, 85, 86, 102
- Calcium influx
evoked by extracellular potassium, 18
evoked by NMDA-receptor activation, 18
gabapentin and pregabalin effects on, 103, 104-107
- Carbamazepine
action mechanisms of, 47, 48-49, 56, 126t, 134
binding to sodium channel, 47
enhancement of GABA-mediated currents by, 94
modulation of potassium channels by, 112
seizures induced by, xii
sodium current block by, 48-49, 50t, 134
persistent sodium current, 56t
reversed by removal of fast inactivation, 47-51, 54t
structure of, 143
- Carbonic anhydrase, 127t, 128
- Cation-chloride co-transporter, 67-68, 67
- Cell-attached recordings, 20-21
- Cellular electrophysiology, 29-39
ion channels, 29-35, 32-33, 34t
synaptic physiology, 35-36
- Central nervous system
excitation in (glutamate-mediated), 36, 71
excitatory synapse and modulators, 134-135

- Central nervous system (*continued*)
inhibition in (GABA-mediated), 35, 59, 64
developmental changes in, 66-68, 67
inhibitory synapse and modulators, 136-137, 140
- Channels. See *Ion channels*.
- Chloride conductance, 38
cation-chloride co-transporters, 67-68, 67
enhanced by benzodiazepines and barbiturates, 23, 61, 66, 136, 140
GABA_A receptor function and, 62-63, 66, 140
reversal of conventional GABA_A effect, 35, 67-68, 67
- Classification of seizures, 25-29, 30-31
- Clobazam
modulation of GABA_A receptors by, 65t
structure of, 143
- Clonazepam
action on zonisamide binding, 128
modulation of GABA_A receptors by, 65t
structure of, 143
- Clorazepate
modulation of GABA_A receptors by, 65t
structure of, 143
- CNQX, 81, 82
- CNS disorders, potassium channel agonists/antagonists and, 119, 120-121
- Cognition disorders, potassium channel antagonists and, 119, 120-121
- Dendritic HCN channels. See *HCN channels*.
- Depolarization, 29, 35, 134
GABA-induced, 67-68, 67
- Depression, potassium channel antagonists and, 119, 120-121
- Developmental changes in GABAergic inhibition, 66-68, 67
- Diazepam
chloride current enhanced by, 66
modulation of GABA_A receptors by, 65t
subunit specificity of, 65
structure of, 143
- Dynorphin, 113
- EEG. See *Electroencephalogram (EEG)*.
- Electrical synapses, 34t
- Electroencephalogram (EEG)
normal vs seizure, 26-28, 29, 30-33, 40-41, 138-139
of primary generalized seizure, 29
surface vs depth, 25, 26, 133, 138
- Electrophysiology
cell-attached recordings, 20-21
cellular, overview of, 29-39
extracellular recordings, 22
ion channels, overview of, 29-35
methods in, 18-23
- Electrophysiology (*continued*)
of normal vs epileptiform activity, 26-28, 29, 30-33, 40-41, 138-139
patch-clamp, 18, 19, 20-21
single-channel recording, 20-21, 23
studies of epilepsy mechanisms, 32-33, 38, 40-41
whole-cell recording, 20-21, 22
- Epilepsy. See also *Seizures*.
animal models of, 15, 94, 97, 100, 101
definition of, 25
heterogeneity in, 29, 39, 123
key channels and receptors in, 34t
mutations associated with, xiii, 23-24, 113
partial-onset, AEDs used to treat, 47, 48-49, 65t
pediatric, felbamate effectiveness in, 77, 125
- Epileptiform bursting
electrophysiology of, 22, 26-28, 29, 30-33, 40-41
GABAergic modulation and, 59, 94
NMDA receptor blockade and, 36
persistent sodium current and, 51
sodium channel modulation and, 47, 132t
- EPSPs. See *Excitatory postsynaptic potentials (EPSPs)*.
- Ethosuximide
block of persistent sodium current by, 56t
inhibition of T-type calcium channels by, 87, 93, 126t
structure of, 143
- Excitatory input, in normal neuronal firing, 32-33
- Excitatory neurotransmitter (glutamate), 36, 71, 74, 134-135
- Excitatory postsynaptic potentials (EPSPs)
in abnormal neuronal firing, 37, 40-41
AMPA receptors and, 34t, 36, 38, 39
NMDA receptors and, 34t, 36, 38, 39, 75
in normal neuronal firing, 32-33, 34t, 40-41
- Excitatory synaptic transmission, 36, 134-135
calcium channels and, 104-105
central excitatory synapse and modulators, 134-135
GABA-mediated, 67-68, 67
glutamate-mediated, 36, 71, 74, 75
- Extracellular recordings, 22
- Familial epileptic conditions, 23-24
benign familial neonatal convulsions (BFNC), xiii, 24, 113
- Felbamate (FBM), 125, 126t, 134-135
broad spectrum of activity of, 125
chloride conductance enhanced by, 136
clinical usefulness of, 81-83
effectiveness in pediatric epilepsy, 77, 125
modulation of GABA_A receptors by, 61, 64, 65, 65t, 125, 126t
subunit specificity in, 65-66, 125
modulation of NMDA receptors by, 76t, 77, 78-80, 125, 126t, 135

Felbamate (FBM) (*continued*)

side effect profile of, 77, 125

structure of, 144

Field recordings, 27-28, 139

FlexStation Reader, 17

FLIPRTETRA System, 17

Flumazenil, 128

Flunitrazepam, 128

Fluorescent imaging, 16-18, 17

Focal seizures, 25, 30-31

GABA (gamma-aminobutyric acid), 35, 59, 136. See also *GABAergic modulators*.

central inhibition mediated by, 35, 59, 64, 136, 140

developmental changes in, 66-68, 67

channel opening in response to, 19

GABA-induced depolarization, mechanisms of, 67-68, 67

GABAergic neuron, receptors, and modulator, 140

glutamate binding of kainate receptors and, 82

reuptake of, 68, 132t

structure of, 60

synthesis and degradation of, 60

GABA transaminase, 68

GABA transporter (GAT), 64, 136, 140

GABA_A receptors, 136, 140

AED modulation of, 61-66, 68, 94, 126t-127t, 136, 140

subunit specificity in, 65-66, 125

antagonists, as convulsants, 61

in central inhibitory synapse, 64, 140

chloride conductance and, 23, 62-63, 66

clinically important modulators of, 61-68, 65t

developmental changes in, 66-68, 67

ionotropic, 59

phasic vs tonic inhibition involving, 64

positive modulators, as anticonvulsants, 61

reversal of conventional GABA_A effect, 35

role in normal and epileptic firing, 34t, 35

structure and subunits of, 59, 61, 62-63, 65-66

synaptic vs extrasynaptic location of, 61, 64

GABA_B receptors, 34t, 35, 59

activation of, 68

antagonists of, 93

GABAergic modulators, 59-69, 126t-127t. See also *GABA_A receptors*;

GABA_B receptors.

central inhibitory synapse and modulators, 64, 136-137

clinically important modulators of, 61-68, 65t

deactivation of T-type calcium channels by, 94

developmental changes and, 66-68, 67

effects on thalamocortical activity, 94

exacerbation of discharges and seizures by, 61, 94

GABAergic modulators (*continued*)

mechanisms of, 59-61, 64, 126t-127t, 132t

phasic vs tonic inhibition and, 61, 64

subunit-specific modulation, 65-66

synaptic vs extrasynaptic receptors and, 61, 64

Gabapentin

action on neurotransmitter release, 103, 104-107

binding to calcium channel $\alpha 2\delta$ subunits, 100-103, 102, 126t, 134

h-current enhancement by, 92, 135

interaction with presynaptic proteins, 103, 106-107

modulation of glutamate receptors by, 76t

radioligand binding studies of, 103

structure of, 144

γ -Aminobutyric acid. See *GABA*.

Gene knock-out and knock-in technologies, 24

General anesthetics, modulation of GABA_A receptors by, 64

Generalized epilepsy with febrile seizures plus (GEFS+), 24

Generalized seizures, 25-29, 31

Genetic Absence Epileptic Rat of Strasbourg (GAERS), 94, 97

Genetic approaches, in defining MOAs, 23-24

Genetic factors and familial epileptic conditions, xiii, 24, 112-113

Gephyrin (geph), 64

Glutamate

as excitatory neurotransmitter, 36, 71, 74

synthesis, release, and reuptake, potential modulation of, 71, 132t, 134-135

Glutamate receptors, 71-84. See also *specific receptor types*.

AED modulators of, 76t, 77-81, 78-80, 126t-127t, 134-135

antagonists of, 71, 75, 76-77

side effects of, 77, 81

excitatory neurotransmission and, 36, 71, 75, 134-135

ionotropic, 36, 71, 74. See also *AMPA receptors*; *Kainate receptors*;

NMDA receptors.

location and function of, 71, 74

metabotropic, 36, 71, 74. See also *Metabotropic glutamate receptors*.

structure and subunits of, 72-73, 76, 76t

subtypes of, 71, 72-73

Glutamic acid decarboxylase, 35

Glycine, 76t

H-currents, 87-92, 93

AEDs and, 92, 126t, 135

HCN (hyperpolarization-activated cyclic nucleotide-gated cation)

channels, 87-93, 132t, 135

absence seizures and, 90-91, 92, 93-94

actions on neuronal excitability, 87-92, 93

h-currents and, 87-92, 93

location of, 87, 135

negative-feedback property of, 87-92

HCN (hyperpolarization-activated cyclic nucleotide-gated cation) channels (*continued*)
structure and subunits of, 87, 92
thalamocortical rhythmicity and, 87-93, 91
High-voltage activated (HVA) calcium channels, 85, 86, 100-103
Hyperpolarization, 35, 67, 68
Hyperpolarization-activated cyclic nucleotide-gated cation (HCN) channels. See *HCN channels*.

Ictal state. See *Seizures*.

Inhibitory input

neuronal network considerations, 37
in normal neuronal firing, 32-33

Inhibitory neurotransmitters, 35, 59

Inhibitory postsynaptic potentials (IPSPs)

in abnormal neuronal firing, 37, 40-41
GABA_A and GABA_B receptors and, 35, 62-63, 68
kainate receptors and, 81, 82
in normal neuronal firing, 32-33, 34t, 40-41

Inhibitory postsynaptic potentials. See *IPSPs*.

Inhibitory synaptic transmission, 35

central inhibitory synapse and modulators, 64, 136-137, 140
developmental changes in, 66-68, 67
modulatory mechanisms, 132t
phasic vs tonic inhibition, 61, 64

Interictal spikes, 40-41, 138-139

PDS as intracellular correlate of, 37-39, 38

Interictal state, electrophysiological activity in, 26-28, 32-33, 37, 38, 40-41

Intracellular recordings, 27-28, 38, 139

Ion channels, 29-35, 34t, 134-141. See also *specific channels*.

conductance changes in epileptiform discharge, 38
ligand-gated receptors, 29-35, 34t
opening of, schematic diagram, 19
overview of, 29-35
roles in normal and epileptic firing, 34t
single-channel recording, 20-21, 23
types of, 29-35, 34t
voltage-dependent, 29, 34t, 131-132, 134-141
calcium channels, 85-87, 100-103
modulators of, 36, 126t-127t
potassium channels, 109-121
sodium channels, 43-58

IPSPs. See *Inhibitory postsynaptic potentials (IPSPs)*.

Kainate receptors, 36, 71, 135. See also *Glutamate receptors*.

AED modulators of, 76t, 77-81, 78-80, 125
ion pore of, 76, 78-80, 135
location and function of, 71, 74, 77-81, 135

Kainate receptors (*continued*)

presynaptic, regulation of IPSP by, 81, 82
subunits of, 76t

KCC2, 67, 68

KCNQ channels, 112-113, 114-115

effects of retigabine on, 116-117

KCNQ2 and *KCNQ3* genes, xiii, 112-113

mutations in, xiii, 113

Kv7.2 and Kv7.3 potassium channels, 110, 112-113, 118. See also *Potassium (K⁺) channels*.

L-type calcium channels, 85, 86

Lacosamide

action mechanism of, 48-49, 50t, 51, 56, 126t, 134-135

sodium channel state and, 48-49

sodium current block unaffected by removal of fast inactivation, 47-51, 54t

structure of, 144

uniqueness of, 49, 51, 56, 135

Lamotrigine

action mechanisms of, 47, 48-49, 56, 126t, 134-135

broad spectrum of, 124

binding to sodium channel, 44-45, 47, 48-49

h-current enhancement by, 92, 126t

modulation of kainate receptors by, 76t

modulation of potassium channels by, 109-112

sodium channel state and, 47, 48-49

sodium current block by, 48-49, 50t, 126t, 134

persistent sodium current, 56t

reversed by removal of fast inactivation, 47-51, 54t

use-dependence of, 47, 50t, 52-53

structure of, 144

Levetiracetam, 97-100, 127t, 134

modulation of kainate receptors by, 76t

modulation of potassium channels by, 109

molecular target of, 97-100, 98-99, 134

radioligand binding studies of, 100, 101

structure of, 144

uniqueness of, 100

Lidocaine, sodium current block by, 49

Ligand-gated ion channels, 29-35, 34t

Linopridine, 113

Local anesthetics, sodium current block by, 48-49

Lorazepam

modulation of GABA_A receptors by, 65t

structure of, 145

Low-voltage activated (LVA) calcium channels, 85-87, 86. See also *Calcium channels*.

- M-current, 112-118
 activated by retigabine, xiii, 113-118, *116-117*
- Magnesium (Mg²⁺) ion, block of NMDA receptors by, 76
- Mechanisms of action (MOAs). See also *specific mechanisms*.
 calcium channels, 85-87, 100-103
 classification of, 132t
 GABAergic modulators, 59-69
 glutamate receptors, 71-84
 HCN channels, 87-93
 methods used to define, 15-24
 multiple or unknown mechanisms, x-xi, 123-130
 potassium channels, 109-121
 reasons for study of, x-xiv, 94
 sodium channels, 43-58
 summary of, 126t-127t
 synthesis and perspectives on, 131-142, *134-137*
 technology and, development of seizure control through, 133-142, *138-141*
- Mephobarbital, 65t
- Meprobamate, 65t
- Metabotropic glutamate receptors, 36, 71. See also *Glutamate receptors*.
 location and function of, 71, 74
 second messenger systems for, 74
 structure and subunits of, 72-73
- Methods for defining MOAs, 15-24, 16t
 electrophysiological approaches, 18-23
 fluorescent imaging, 16-18, 17
 molecular and genetic approaches, 23-24, 133
 radiolabeled receptor binding studies, 15-16
- Midazolam
 modulation of GABA_A receptors by, 65t
 structure of, 145
- Molecular methods, 23-24, 133
- Molecular target, confirming, 23
- Multiple sclerosis, potassium channel antagonists and, 119, *120-121*
- Muscarinic-regulated potassium current. See *M-current*.
- Mutagenesis, site-directed, 23-24
- Mutations
 in *KCNQ2* and *KCNQ3* genes, xiii, 113
 molecular techniques and, 23-24
 in receptors and ion channels, 23-24
- N-methyl-D-aspartate receptors. See *NMDA receptors*.
- N-type calcium channels, 85, 86
- Networks, neuronal
 abnormal firing and, 37, *40-41*
 in epilepsy, x, 25, 85
- Neuromodulation, 126t-127t
 GABAergic, 59-69, 126t-127t
 glutamatergic, 71-84, 126t-127t
- Neuronal cultures, primary, 18
- Neuronal firing
 abnormal, 37-39, *40-41*
 key channels and receptors in, 34t
 normal, 32-33
- Neuronal networks. See *Networks, neuronal*.
- Neurons, normal vs epileptic, 25-42. See also *Neurophysiology*.
 electrophysiology of, 29, *30-31*
- Neurophysiology, 25-42
 cellular electrophysiology, 29-39
 abnormal neuronal firing, 37-39
 ion channels, 29-35
 synaptic physiology, 35-36
 classification of seizures, 25-29, *30-31*
 electroencephalograms (EEGs), 26-28, 29, *30-33, 40-41, 138-139*
 excitatory and inhibitory inputs in neuronal firing, *32-33*
- Neurosteroids, modulation of GABA_A receptors by, *64, 140*
- Neurotransmitters
 excitatory (glutamate), 36
 inhibitory (GABA), 35
 release of
 calcium channels and, 103, *104-107*
 loading and release from synaptic vesicles, *98-99*
 voltage-dependent ion channels and, 132, *134-137*
- Nitrazepam, 145
- NKCC1, 67, 68
- NMDA receptors, 71-77. See also *Glutamate receptors*.
 activation of, 36
 AED modulator of (felbamate), 76t, 77, *78-80, 125, 126t, 135*
 antagonists of, 71, 75, *76-77, 81*
 blockade of, 36
 EPSPs and, 34t, 36, 38, 39, 75
 ion pore of, 76, *78-80, 135*
 location and function of, 71, 74, *135*
 Mg²⁺ block of, 76
 role in excitatory neurotransmission, 34t, 36, 71, 75
 structure and subunits of, 72-73, 76, 76t
- Non-NMDA receptors. See *AMPA receptors; Kainate receptors*.
- Oxcarbazepine
 action mechanism of, 47, *48-49, 127t, 134*
 binding to sodium channel, 47, *48-49*
 enhancement of GABA-mediated currents by, 94
 modulation of potassium channels by, 109
 sodium current block by, 47, *48-49, 134*
 structure of, 145

- P/Q-type calcium channels, 85, 86
- Pain, potassium channel agonists and, 119, 120-121
- Paroxysmal depolarization shift (PDS), 37-39, 38, 40-41, 131-132
 channels and receptors in, 34t
 late sodium channel openings and, 51
- Partial-onset epilepsy, AEDs used to treat, 47, 48-49, 65t
- Patch-clamp electrophysiology, 18-23, 19, 20-21
 combined with molecular biology, 23, 133
 need for testable hypothesis in, 22
- PDS. See *Paroxysmal depolarization shift*.
- Pediatric epilepsy, felbamate effectiveness in, 77, 125
- Persistent sodium current, 51-56, 55, 56t
- “Petit mal” seizures. See *Absence seizures*.
- Phasic inhibition, 61, 64
- Phenobarbital
 chloride current enhanced by, 66
 modulation of GABA_A receptors by, 65t, 66, 126t
 modulation of kainate receptors by, 76t
 modulation of potassium channels by, 109
 structure of, 145
- Phenytoin
 action mechanisms of, 47, 48-49, 51-56, 134
 binding site for, 23
 binding to sodium channel, 47, 48-49
 modulation of glutamate receptors by, 76t
 seizures induced by, xii
 sodium current block by, 48-49, 50t, 126t, 134
 persistent sodium current, 51-56, 55, 56t
 reversed by removal of fast inactivation, 47-51, 54t
 structure of, 145
- Phosphoinositide, 36
- Phospholipases C & D, 36
- Pilocarpine, 113
- Postsynaptic membrane, ion channels located in, 135, 137
- Potassium-evoked calcium influx, 18
- Potassium (K⁺) channels, 109-121, 132t
 calcium-dependent, 34t, 110-111
 GABA_B receptors and, 68
 gene superfamily for, 109, 110-111, 112
 retigabine and, 113-118, 116-117, 127t
 role in normal and epileptic firing, 34t, 109
 subunits of, genes encoding (*KCNQ2*, *KCNQ3*), xiii
 voltage-dependent, 34t, 109-121
 A-type, 109-112, 112t
 activation of, 132t
 AED modulators of, 109-118
 functions of, 109
 KCNQ, 112-113, 114-115
- Potassium (K⁺) channels, voltage-dependent (*continued*)
 Kv7.2 and Kv7.3, 110, 112-113, 118
 agonists and antagonists of, 118, 120-121, 127t
 genes for, 112-113
 localization of, 113, 114-115
 M-current and, 112-118
 M-type, 112t
 properties of, 112t
 structure and subunits of, 110-111
 types of, 109, 110-111, 112t
- Potassium current (M-current), 112-118
 activation by retigabine, xiii, 113-118, 116-117
- Pregabalin
 action on neurotransmitter release, 103, 104-107
 binding to calcium channel $\alpha_2\delta$ subunits, 100-103, 102, 127t, 134
 interaction with presynaptic proteins, 103, 106-107
 radioligand binding studies of, 103
 structure of, 146
- Presynaptic proteins, 103, 106-107
- Presynaptic synaptic vesicle 2A (SV2A), 97-100, 98-99, 101
- Primary generalized seizures, 25-29, 31
- Primary neuronal cultures, 18
- Primidone
 modulation of GABA_A receptors by, 65t
 structure of, 146
- Propanediol dicarbamates, 65t
- Propofol, 65t
- R-type calcium channels, 85, 86
- Radiolabeled receptor binding studies, 15-16
- Receptor channels. See *Ion channels*.
- Receptors, 34t. See also *Ion channels*; *specific receptors*.
 AMPA, 34t
 GABA, 35
 glutamate, 36
 neurotransmitter binding to, 35
 NMDA, 34t
 non-NMDA, 34t
 radiolabeled receptor binding studies, 15-16
- Refractory period, 47
- Resting potential, 32-33
- Retigabine, 127t
 activation of M-current by, xiii, 113-118, 116-117
 development of, xiii
 phase 3 registration trials for, 118
 structure of, 146
- Rufinamide, 127t, 129, 134
 structure of, 146

Schizophrenia, potassium channel agonists and, 119, 120-121

Second messenger systems, for metabotropic glutamate receptors, 74

Seizures

- absence (“petit mal”). See *Absence seizures*.
- AED-induced exacerbation of, xii-xiii, 61, 94
- audiogenic, mouse model of, 100, 101
- classification of, 25-29, 30-31
- clinically important GABA_A receptor modulators for, 65t
- EEG during, 25-29, 26-28, 30-31, 30-33, 38, 40-41, 138-139
- example of technology and MOAs leading to seizure control, 133-142, 138-141
- factors mediating, 39
- focal vs generalized, 25-29, 30-31
- focal with secondary generalization, 30
- generalized, 25-29, 31
 - treatment of, 65t
- as imbalance between inhibition and excitation, 29
- partial, 25
 - treatment of, 65t
- spread of, 25-29, 30-31
 - AED modulation of neurotransmission and, 132, 134-137

Severe myoclonic epilepsy of infancy (SMEI), 24

Single-channel recording, 20-21, 23

SNAP-25, 106-107

SNARE proteins, 106-107

Sodium current

- blockers of, 46-56, 48-49, 50t, 54t, 55, 134-135
- persistent, 51-56, 55
 - blockers of, 51-56, 55, 56t

Sodium (Na⁺) channels, 43-58

- AEDs and, 43, 44-45, 47-51, 48-49, 50t, 126t-127t, 132t, 134-135
- binding of AEDs to, 23, 44-45, 47, 56
- conformational states of, 46, 48-49
 - inactivated state, 46, 48-49
 - AED binding during, 47, 56
 - open state, 46, 48-49
 - resting (closed) state, 46, 48-49
- inactivation of, 46-47
 - AED actions on, 43, 44-45, 48-49
 - fast vs slow inactivation, 46-47, 50t
 - lacosamide enhancement of slow inactivation, 48-49, 50t, 51
 - removal of fast inactivation, 47-51, 54t
- isoforms of, 43-46
- late openings of (persistent sodium current), 51-56, 55
- pharmacology, physiology, and functional consequences of
 - modulation of, 50t, 132t, 134-135
- pore of, 44-45, 46
- role in normal and epileptic firing, 29, 34t, 43
- sodium movement contribution to action potential, 29, 43

Sodium (Na⁺) channels (*continued*)

- structure and subunits of, 43, 44-45, 51
- use-dependent block of, 47, 50t, 52-53

Sodium-potassium pump, 32-33, 34t

Somatostatin, 113

Status epilepticus, AEDs for, 65t

Sulfamate, 65t

SV2A. See *Synaptic vesicle protein (SV2A)*.

Synaptic physiology, 35-36. See also *Excitatory synaptic transmission*; *Inhibitory synaptic transmission*.

- electrical synapses, 34t
- excitatory transmission, 36
 - excitatory CNS synapse and modulators, 134-135
- inhibitory transmission, 35
 - inhibitory CNS synapse and modulators, 136-137
 - phasic vs tonic inhibition, 61, 64
 - neurotransmitter release, 98-99, 104-105
 - postsynaptic membrane, 135, 137

Synaptic vesicle protein (SV2A), 97-100, 98-99, 101, 134

Synaptic vesicles, neurotransmitter loading and release from, 98-99, 132t

Synaptobrevin (VAMP), 106-107

Synaptotagmin-1, 106-107

Syntaxin-1, 106-107

T-type calcium channels. See *Calcium channels*.

Thalamic relay neurons, 90-91

Thalamic reticular neurons, 90-91, 94

Thalamocortical connections, 25-29, 30-31

- modulatory pathways affecting seizure activity, 90-91

Thalamocortical rhythmicity and discharges, 90-91

- HCN channels and, 87-93, 91
- T-type calcium channels and, 86-87, 91

Tiagabine, 68, 127t, 136

- development of, 15
- seizure precipitation by, 94
- structure of, 146

Tonic inhibition, 61, 64

- absence seizures promoted by augmentation of, 61

Topiramate (TPM), 125-128, 127t, 134-135

- block of persistent sodium current by, 56t, 125, 127t, 134
- chloride conductance enhanced by, 136
- clinical usefulness of, 81-83
- inhibition of carbonic anhydrase by, 127t, 128
- modulation of AMPA and kainate receptors by, 76t, 77-81, 78-80, 125, 127t, 135
- modulation of GABA_A receptors by, 61-65, 64, 65t, 127t, 128
- subunit specificity of, 65

Topiramate (TPM) (*continued*)

modulation of potassium channels by, 109

structure of, 147

Transmembrane potential, 32-33

Use-dependent sodium channel blockers, 47, 50t, 52-53

Valproate, block of persistent sodium current by, 56t

Valproic acid (VPA), 124, 126t, 134

inhibition of T-type calcium channels by, 87, 124

structure of, 147

Vigabatrin, 68, 127t, 136

development of, 15

seizure precipitation by, 94

structure of, 147

Voltage-dependent ion channels, 29, 34t, 131-132. See also *Calcium channels; Potassium channels; Sodium channels.*

AED modulation of, 126t-127t

modulators of, 36

schematic summary of, 134-141

Whole-cell patch-clamp recording, 20-21, 22

Window current, 51

Zonisamide (ZNS), 127t, 128, 134

inhibition of carbonic anhydrase by, 127t, 128

inhibition of T-type calcium channels by, 87, 127t, 128

structure of, 147